Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
← catalyst calendarNCT07527858 · readout ≤ 865 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
170estimated
Sites
14
Countries
Australia, South Korea, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-19 | actual | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Microsatellite Stable Colorectal Cancer
Interventions
- Drug: Denikitug — also filed as GS-1811, DEN
- Drug: Nivolumab — also filed as NIVO
- Drug: Bevacizumab — also filed as BVZ
- Drug: Trifluridine-Tipiracil — also filed as FTD-TPI
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured Up to 60 months
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed